Follow the NEWLINK GENETICS CORP stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €147.7m. The latest transaction was filed on 4 February 2016 (Cession). Among the most active insiders: Link Charles J. Jr.. The full history is openly available.
18
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
13 ops.
Sell Volume
Fundamental score
Ranked 28,772 of 29,051 companies
7.1
score / 100
Value
4
Quality
10
FCF yld-30%
Earn yld-127%
EV/EBITDA·
ROE-29%
Gross mgn14%
Net mgn-61%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
NEWLINK GENETICS CORP is a biopharmaceutical company focused on developing immunotherapy treatments for cancer and other diseases. It is listed on NASDAQ under the ticker NLNK.